| [1] |
Bowlus CL, Pockros PJ, Kremer AE, et al. Long-term obeticholic acid therapy improves histological endpoints in patients with primary biliary cholangitis. Clin Gastroenterol Hepatol, 2020, 18:1170-1178.e6.
|
| [2] |
FDA Adds Black Box Warning to Intercept’s Liver Disease Medicine. https://www.fdanews.com/articles/ 185509- fda- adds- black- box- warning- to- intercepts- liver-disease-medicine (9 October 2019, date last accessed).
|
| [3] |
Nevens F, Andreone P, Mazzella G, et al. A placebo- controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med, 2016, 375: 631-643.
|
| [4] |
Eaton J, Vuppalanchi R, Reddy R, et al. Liver injury in patients with cholestatic liver disease treated with obeticholic acid. Hepatology, 2020, 71:1511-1514.
|
| [5] |
FDA: Obeticholic Acid. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/207999s003lbl.pdf (9 October 2019, date last accessed).
|
